Compare UBFO & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | UBFO | MOLN |
|---|---|---|
| Founded | 1987 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 183.4M | 151.2M |
| IPO Year | N/A | 2021 |
| Metric | UBFO | MOLN |
|---|---|---|
| Price | $10.63 | $4.15 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.38 |
| AVG Volume (30 Days) | ★ 31.9K | 5.9K |
| Earning Date | 01-22-2026 | 03-05-2026 |
| Dividend Yield | ★ 4.60% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $48,283,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $999.99 |
| P/E Ratio | $14.90 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.32 | $3.36 |
| 52 Week High | $11.05 | $5.35 |
| Indicator | UBFO | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 60.46 | 49.36 |
| Support Level | $10.35 | $3.97 |
| Resistance Level | $11.05 | $4.27 |
| Average True Range (ATR) | 0.26 | 0.17 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 62.50 | 53.65 |
United Security Bancshares operates as the holding for United Security Bank. It provides commercial banking services to the business and professional community, and individuals located in Fresno, Madera, Santa Clara, and Kern Counties. It offers checking and savings accounts, deposits, mortgage loans, credit and debit cards, safe deposit boxes, automated teller machines, wire transfers, money market accounts, mobile banking, and wealth management services. The company's primary sources of revenue are interest income from loans and investment securities.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.